Evommune, Inc.
NYSE:EVMNBiotechnology
-$0.17 today
- Market cap
- $284.49M
- Beta
- 0.10
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.26
Volume 0.60M
Average 0.38M
EVMN Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Evommune, Inc.NYSE: EVMN
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin grows 90.9% year over year
Q1 FY2026 selling, general & admin of $6.29M rose 90.9% year over year. Sequentially, it fell 32.5% from the prior quarter.
Context
- Selling, general & admin amounted to 154.1% of revenue in FY2025, down 10.0 pp from a year earlier.
- Selling, general & admin increased in 2 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 6 analysts of $1.72M (-91.4%) for the fiscal year ending Dec 2026, a slowdown from the +74.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $6.29M-32.5% QoQ
- Last fiscal yearDec 2025
- $20.03M+74.4% YoY
- LTMMar 2026
- $22.64M— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +90.9% | -31.8% | -122.7 pp |
| 1 year | +74.4% | -91.4% | -165.9 pp |
| 3-year CAGR | — | -44.4% | — |
| 5-year CAGR | -8.9% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 20.03M USD
- Year-over-year change
- +74.4%
- 2-year CAGR
- +42.6%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 20.03M | +74.4% |
| FY2024 | 2024-12-31 | 11.48M | +16.5% |
| FY2023 | 2023-12-31 | 9.85M | — |
Selling, General & Admin vs competitors
How EVMN compares with its peers on the latest reported figures
- EVMN's LTM Mar 2026 selling, general & admin of $22.64M is the 8th highest of the 10 companies compared; the peer median is $53.04M.
- Selling, general & admin amounts to 226.4% of revenue for EVMN, versus a peer median of 69.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $15.14B | +24248.6% | -5.7% | 5694.1% | |
FTREFortrea Holdings Inc. | LTM Jun 2026 | $412.4M | -22.3% | +3.1% | 15.4% |
| LTM Mar 2026 | $104.54M | -7.7% | -10.2% | 69.2% | |
| LTM Jun 2026 | $103.43M | +16.1% | +9.7% | 35.6% | |
| LTM Mar 2026 | $53.04M | +1.3% | -5.0% | 696.5% | |
| LTM Mar 2026 | $43.75M | -19.9% | -3.4% | 56.0% | |
| LTM Mar 2026 | $26.47M | -12.7% | +5.5% | 91.6% | |
EVMNEvommune, Inc. | LTM Mar 2026 | $22.64M | — | — | 226.4% |
CLYMClimb Bio, Inc. | LTM Mar 2026 | $21.29M | +7.5% | +3.8% | — |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $20.27M | +8.2% | -0.8% | — |
| Peer median (excluding EVMN) | $53.04M | +1.3% | -0.8% | 69.2% | |
Competitors are the stored peer set for EVMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Revenue | 5M | 7M | 13M |
| Cost of Revenue | 1M | 1.29M | 0 |
| Gross Profit | 4M | 5.71M | 13M |
| Gross Margin | 80.0% | 81.6% | 100.0% |
| Research & Development | 32M | 64.24M | 74.04M |
| Selling, General & Admin | 9.85M | 11.48M | 20.03M |
| Operating Expenses | 41.85M | 75.73M | 94.07M |
| Depreciation & Amortization | 1M | 1.29M | 1.39M |
| EBITDA | (33M) | (65.49M) | (67.48M) |
| EBITDA Margin | -659.9% | -935.5% | -519.1% |
| Operating Income | (37.85M) | (70.01M) | (81.07M) |
| Operating Margin | -757.0% | -1000.2% | -623.6% |
| Interest Income | 3.86M | 3.24M | 3.32M |
| Interest Expense | 58K | 34K | 0 |
| Other Income / Expenses | 3.8M | 3.2M | 12.2M |
| Income Before Tax | (34.05M) | (66.81M) | (68.87M) |
| Pre-Tax Margin | -681.1% | -954.4% | -529.8% |
| Income Tax Expense | 0 | 0 | 0 |
| Net Income | (34.05M) | (66.81M) | (68.87M) |
| Net Margin | -681.1% | -954.4% | -529.8% |
| EPS (Basic) | (1.13) | (2.27) | (2.18) |
| EPS (Diluted) | (1.13) | (2.27) | (2.18) |
| Weighted Avg Shares | 30.08M | 30.08M | 31.52M |
| Weighted Avg Shares (Diluted) | 30.08M | 30.08M | 31.52M |
Evommune, Inc.
NYSE:EVMN
Intrinsic Alpha fair value
Locked
Current Price
$6.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.